Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Wuhan Healthgen Biotechnology Days Payable?
Wuhan Healthgen BiotechnologySHSE:688765 +4.66%19 Days Payable is 6,352.41 as of Mar. 2026, which is 285% above its 10-year median of 1,649.96. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 927 Drug Manufacturers companies, Wuhan Healthgen Biotechnology ranks better than 98.49% on this metric.
The historical rank and industry rank for Wuhan Healthgen Biotechnology's Days Payable or its related term are showing as below:
SHSE:688765'
s Days Payable Range Over the Past 10 Years
Min: 175.85 Med: 1649.96 Max: 10917.69
Current: 3523.07
During the past 12 years, Wuhan Healthgen Biotechnology's highest Days Payable was 10917.69. The lowest was 175.85. And the median was 1649.96.
SHSE:688765's Days Payable is ranked better than 98.49% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SHSE:688765: 3523.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Healthgen Biotechnology Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Wuhan Healthgen Biotechnology's Days Payable falls into.
Wuhan Healthgen Biotechnology Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Healthgen Biotechnology (SHSE:688765) has a Days Payable of 6,352.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wuhan Healthgen Biotechnology and its competitors. This is 285% above median its historical median of 1,649.96. Over the past decade, Wuhan Healthgen Biotechnology's Days Payable has ranged from 175.85 to 10,917.69. According to the industry distribution chart, Wuhan Healthgen Biotechnology ranks #14 out of 927 companies in the Drug Manufacturers industry, placing it in the top 1.5%.
Is Wuhan Healthgen Biotechnology's Days Payable too high?
Wuhan Healthgen Biotechnology's current Days Payable of 6,352.41 is 285% above median its 10-year median of 1,649.96. Over the past 10 years, this metric has ranged from a low of 175.85 to a high of 10,917.69. The Drug Manufacturers industry median Days Payable is 90.38. Wuhan Healthgen Biotechnology's value of 6,352.41 is 6928.6% above this industry median. Based on the distribution chart, Wuhan Healthgen Biotechnology ranks #14 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wuhan Healthgen Biotechnology ranks #14 out of 927 companies for Days Payable. This places Wuhan Healthgen Biotechnology in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Wuhan Healthgen Biotechnology's value of 6,352.41 is 6928.6% above this benchmark. Historically, Wuhan Healthgen Biotechnology's own Days Payable has ranged from 175.85 to 10,917.69 over the past decade. While the company's 10-year median is 1,649.96 vs. the industry median of 90.38, Wuhan Healthgen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan Healthgen Biotechnology's current Days Payable of 6,352.41 is 6928.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current Days Payable is 6,352.41, which is 285% above median its own 10-year median of 1,649.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Days Payable of 6,352.41. The current Days Payable is 6,352.41, which is 285% above median its 10-year median of 1,649.96 and 6928.6% above the Drug Manufacturers industry median of 90.38. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Days Payable is 6,352.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan Healthgen Biotechnology Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688765 has been successfully added to your 
